|
|
| | (E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole Basic information |
| Product Name: | (E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole | | Synonyms: | (E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole;6-Iodo-3-[(1E)-2-(2-pyridinyl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-Indazole;(E)-6-iodo-3-(2-(pyridin-2-yl)vinyl)-1-(tetrahydro-2H-pyran-2-yl);6-iodo-3-((E)-2-(pyridin-2-yl-vinyl)
-1-(tetrahydropyran-2-yl)-1H-indazole;6-iodo-1-(oxan-2-yl)-3-(2-pyridin-2-ylethenyl)indazole;6-Iodo-3-(2-pyridin-2-yl-vinyl)-1-(tetrahydro-pyran-2-yl)-1H-indazole;1H-Indazole, 6-iodo-3-[(1E)-2-(2-pyridinyl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-;(E)-6-LODO-3-{2-(PYRIDIN-2-YL)ETHENYL}-1-(TETRAHYDRO-2H-PYRAN-2-YL)-1H-INDAZOLE | | CAS: | 886230-77-9 | | MF: | C19H18IN3O | | MW: | 431.27 | | EINECS: | 1312995-182-4 | | Product Categories: | Intermediate of Axitinib;intermediate | | Mol File: | 886230-77-9.mol | ![(E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole Structure](CAS2/GIF/886230-77-9.gif) |
| | (E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole Chemical Properties |
| Melting point | 156-159°C | | Boiling point | 561.2±50.0 °C(Predicted) | | density | 1.60 | | storage temp. | 2-8°C(protect from light) | | solubility | Chloroform, DMSO, Methanol | | pka | 4.25±0.10(Predicted) | | form | Solid | | color | Light Yellow | | Stability: | Hygroscopic, Light Sensitive |
| | (E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole Usage And Synthesis |
| Uses | (E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole is an intermediate used to prepare Axitinib (A794650) . Axitinib is used in cancer therapy.
Axitinib (AG-013736) is a selective small molecule inhibitor of VEGF receptor tyrosine kinases 1, 2 and
3 and the platelet-derived growth factor (PDGF) receptor that targets the catalytic domain of the
tyrosine kinase and induces ATP-competitive inhibition with limited activity against other protein
kinases . It is an indazole derivative, its molecular formula is C22H18N4OS and its molecular
weight is 386.5 Da[1].
| | Synthesis | 6-amino-3-((E)-2-pyridin-2-yl-vinyl)-1-(tetrahydropyran-2-yl)-1 H-indazole (100 g) dissolved in
acetic acid (6.5 L) is added over 1.5 hours to a solution of sodium nitrite (35 g) dissolved in
water (3.0 L) at 0℃ (-3 ± 3°C). The mixture is stirred for 1 hour at 0℃, and a solution of
hydrochloric acid (560 mL diluted in 1 L of water) at 0℃ is added over 15 minutes. The mixture
is stirred for 1 hour at 0℃. The formation of the diazonium salt is monitored by HPLC.
Dicholoromethane (400 ml) at O0C is added over 10 minutes to the diazonium salt solution at
0℃, and a solution of potassium iodide (207. 25 g) dissolved in water (300 ml) at O0C is added
over 1.5 hours. The reaction mixture is agitated for 3 hours at 0℃ (until complete by HPLC).
The mixture is then poured into a solution of sodium bisulfite in process water [Sodium bisulfite
(200g) dissolve in process water (500mL) at 27± 3°C] and Dicholoromethane (400 ml) below
270C, agitated, and the layers separated. The aqueous layer is extracted with Dichloromethane (100 ml) at 27℃ and combined. A solution of aqueous ammonia (100 ml) at 27± 3°C is added
over 40 minutes to the combined organic layers until the aqueous phase is basic (pH = 9 to 12).
Distill out dichloromethane and add methanol and heat to 50 ± 3°C and stir it at this temperature
for 15 min and then stir for 30 min at RT, followed by washing with methanol. Add
dichloromethane and heat to 45± 3°C and add activated carbon at this temperature. Followed by
addition of methanol and dichloromethane (if required) and stir the reaction mixture at 27± 3°C
for 30 min and cool it to 0±3°C and stir 1 hr and wash with methanol to provide (E)-6-Iodo-3-[2-
(pyridine-2yl)ethenyl]-1 -(tetrahydro-2H- pyran-2-yl)-1H-indazole. | | References | [1] LESLIEISLA. Avelumab and axitinib in the treatment of renal cell carcinoma: safety and efficacy.[J]. Expert Review of Anticancer Therapy, 2020, 20 5: 343-354. DOI:10.1080/14737140.2020.1756780. |
| | (E)-6-Iodo-3-[2-(pyridin-2-yl)ethenyl]-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole Preparation Products And Raw materials |
|